移植前赖氨酸(K)特异性甲基转移酶2A(KMT2A)部分串联重复水平可预测单倍体供体造血干细胞移植后急性髓性白血病患者的复发情况。

IF 1.5 Q3 HEMATOLOGY 血液科学(英文) Pub Date : 2024-09-25 eCollection Date: 2024-10-01 DOI:10.1097/BS9.0000000000000207
Dao-Xing Deng, Xiao-Hang Ma, Ze-Hua Wu, Xiao-Hui Zhang, Lan-Ping Xu, Yu Wang, Chen-Hua Yan, Huan Chen, Yu-Hong Chen, Wei Han, Feng-Rong Wang, Jing-Zhi Wang, Xiao-Jun Huang, Xiao-Su Zhao, Xiao-Dong Mo
{"title":"移植前赖氨酸(K)特异性甲基转移酶2A(KMT2A)部分串联重复水平可预测单倍体供体造血干细胞移植后急性髓性白血病患者的复发情况。","authors":"Dao-Xing Deng, Xiao-Hang Ma, Ze-Hua Wu, Xiao-Hui Zhang, Lan-Ping Xu, Yu Wang, Chen-Hua Yan, Huan Chen, Yu-Hong Chen, Wei Han, Feng-Rong Wang, Jing-Zhi Wang, Xiao-Jun Huang, Xiao-Su Zhao, Xiao-Dong Mo","doi":"10.1097/BS9.0000000000000207","DOIUrl":null,"url":null,"abstract":"<p><p>We aimed to identify dynamic changes of lysine (K)-specific methyltransferase 2A partial tandem duplications (<i>KMT2A</i>-PTD) before and after haploidentical donor hematopoietic stem cell transplantation (HID HSCT) and explore the prognostic value of pre-transplantation levels of <i>KMT2A</i>-PTD in acute myeloid leukemia (AML) receiving HID HSCT. Consecutive 64 AML patients with <i>KMT2A</i>-PTD positivity at diagnosis receiving HID HSCT were included in this study. Patients with <i>KMT2A</i>-PTD ≥1% before HSCT had a slower decrease of <i>KMT2A</i>-PTD after HID HSCT. Patients with <i>KMT2A</i>-PTD ≥1% before HID HSCT had a higher cumulative incidence of relapse (36.4%, 95% confidence interval [CI]: 6.3%-66.5%) at 2 years after HSCT than those with <i>KMT2A</i>-PTD <1% (7.5%, 95% CI: 0.3%-14.7%, <i>P</i> = .010). In multivariable analysis, <i>KMT2A</i>-PTD ≥1% before HID HSCT was the only independent risk factor for relapse (hazard ratio [HR]: 4.90; 95% CI: 1.22-19.59; <i>P</i> = .025). Thus, pre-transplantation levels of <i>KMT2A</i>-PTD could predict relapse in AML patients following HID HSCT.</p>","PeriodicalId":67343,"journal":{"name":"血液科学(英文)","volume":"6 4","pages":"e00207"},"PeriodicalIF":1.5000,"publicationDate":"2024-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11427034/pdf/","citationCount":"0","resultStr":"{\"title\":\"Pre-transplantation levels of lysine (K)-specific methyltransferase 2A (<i>KMT2A</i>) partial tandem duplications can predict relapse of acute myeloid leukemia patients following haploidentical donor hematopoietic stem cell transplantation.\",\"authors\":\"Dao-Xing Deng, Xiao-Hang Ma, Ze-Hua Wu, Xiao-Hui Zhang, Lan-Ping Xu, Yu Wang, Chen-Hua Yan, Huan Chen, Yu-Hong Chen, Wei Han, Feng-Rong Wang, Jing-Zhi Wang, Xiao-Jun Huang, Xiao-Su Zhao, Xiao-Dong Mo\",\"doi\":\"10.1097/BS9.0000000000000207\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>We aimed to identify dynamic changes of lysine (K)-specific methyltransferase 2A partial tandem duplications (<i>KMT2A</i>-PTD) before and after haploidentical donor hematopoietic stem cell transplantation (HID HSCT) and explore the prognostic value of pre-transplantation levels of <i>KMT2A</i>-PTD in acute myeloid leukemia (AML) receiving HID HSCT. Consecutive 64 AML patients with <i>KMT2A</i>-PTD positivity at diagnosis receiving HID HSCT were included in this study. Patients with <i>KMT2A</i>-PTD ≥1% before HSCT had a slower decrease of <i>KMT2A</i>-PTD after HID HSCT. Patients with <i>KMT2A</i>-PTD ≥1% before HID HSCT had a higher cumulative incidence of relapse (36.4%, 95% confidence interval [CI]: 6.3%-66.5%) at 2 years after HSCT than those with <i>KMT2A</i>-PTD <1% (7.5%, 95% CI: 0.3%-14.7%, <i>P</i> = .010). In multivariable analysis, <i>KMT2A</i>-PTD ≥1% before HID HSCT was the only independent risk factor for relapse (hazard ratio [HR]: 4.90; 95% CI: 1.22-19.59; <i>P</i> = .025). Thus, pre-transplantation levels of <i>KMT2A</i>-PTD could predict relapse in AML patients following HID HSCT.</p>\",\"PeriodicalId\":67343,\"journal\":{\"name\":\"血液科学(英文)\",\"volume\":\"6 4\",\"pages\":\"e00207\"},\"PeriodicalIF\":1.5000,\"publicationDate\":\"2024-09-25\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11427034/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"血液科学(英文)\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1097/BS9.0000000000000207\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/10/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q3\",\"JCRName\":\"HEMATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"血液科学(英文)","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1097/BS9.0000000000000207","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/10/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"HEMATOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

我们旨在确定赖氨酸(K)特异性甲基转移酶2A部分串联重复(KMT2A-PTD)在单倍体供体造血干细胞移植(HID HSCT)前后的动态变化,并探讨接受HID HSCT的急性髓性白血病(AML)患者移植前KMT2A-PTD水平的预后价值。本研究连续纳入了64例诊断时KMT2A-PTD阳性、接受HID造血干细胞移植的急性髓性白血病患者。造血干细胞移植前KMT2A-PTD≥1%的患者在HID造血干细胞移植后KMT2A-PTD下降较慢。造血干细胞移植前KMT2A-PTD≥1%的患者在造血干细胞移植后2年的累积复发率(36.4%,95%置信区间[CI]:6.3%-66.5%)高于KMT2A-PTD患者(P = .010)。在多变量分析中,HID造血干细胞移植前KMT2A-PTD≥1%是复发的唯一独立危险因素(危险比[HR]:4.90;95% CI:1.22-19.59;P = .025)。因此,移植前的KMT2A-PTD水平可预测HID造血干细胞移植后AML患者的复发。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Pre-transplantation levels of lysine (K)-specific methyltransferase 2A (KMT2A) partial tandem duplications can predict relapse of acute myeloid leukemia patients following haploidentical donor hematopoietic stem cell transplantation.

We aimed to identify dynamic changes of lysine (K)-specific methyltransferase 2A partial tandem duplications (KMT2A-PTD) before and after haploidentical donor hematopoietic stem cell transplantation (HID HSCT) and explore the prognostic value of pre-transplantation levels of KMT2A-PTD in acute myeloid leukemia (AML) receiving HID HSCT. Consecutive 64 AML patients with KMT2A-PTD positivity at diagnosis receiving HID HSCT were included in this study. Patients with KMT2A-PTD ≥1% before HSCT had a slower decrease of KMT2A-PTD after HID HSCT. Patients with KMT2A-PTD ≥1% before HID HSCT had a higher cumulative incidence of relapse (36.4%, 95% confidence interval [CI]: 6.3%-66.5%) at 2 years after HSCT than those with KMT2A-PTD <1% (7.5%, 95% CI: 0.3%-14.7%, P = .010). In multivariable analysis, KMT2A-PTD ≥1% before HID HSCT was the only independent risk factor for relapse (hazard ratio [HR]: 4.90; 95% CI: 1.22-19.59; P = .025). Thus, pre-transplantation levels of KMT2A-PTD could predict relapse in AML patients following HID HSCT.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
1.70
自引率
0.00%
发文量
0
审稿时长
10 weeks
期刊最新文献
Dynamic frailty-tailored therapy (DynaFiT): A proof-of-concept study in elderly patients with newly diagnosed multiple myeloma. Pre-transplantation levels of lysine (K)-specific methyltransferase 2A (KMT2A) partial tandem duplications can predict relapse of acute myeloid leukemia patients following haploidentical donor hematopoietic stem cell transplantation. Dual role of BCL11B in T-cell malignancies. Epigenetic modifications in hematopoietic ecosystem: a key tuner from homeostasis to acute myeloid leukemia. Mitochondrial genetic variations in leukemia: a comprehensive overview.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1